Yinhua CSI Innovative Drugs Industry ETF(159992) Rises 2.12% in Early Trading; Assets Under Management Grow by Nearly 1.2 Billion Yuan Over Past 3 Months

NewTimeSpace News: As of 09:41 on March 24, 2026, Innovative Medicine ETF (159992) rose 2.12%, with the latest price at 0.77 yuan. (The stocks listed above are index constituents only, with no specific recommendation intended.)

In terms of liquidity, Innovative Medicine ETF recorded an intraday turnover rate of 0.8%, with trading volume reaching 113 million yuan. Looking at a longer time frame, as of March 23, the ETF's average daily trading volume over the past year was 554 million yuan, ranking first among comparable funds. (Data source: Wind)

In terms of scale, Innovative Medicine ETF's assets under management grew by 1.157 billion yuan over the past three months, achieving significant growth, with the new scale ranking 1st out of 7 comparable funds. (Data source: Wind)

In terms of shares, Innovative Medicine ETF's latest share count reached 18.425 billion shares, hitting a new high for the past month, and ranking 1st out of 7 comparable funds. (Data source: Wind)

Regarding capital inflows, Innovative Medicine ETF recorded a net capital inflow of 101 million yuan most recently. Looking at a longer time frame, over the past 10 trading days, the ETF attracted a total of 46.6021 million yuan in capital. (Data source: Wind)

Data shows that leveraged funds continue to build positions. Innovative Medicine ETF's latest margin purchase amount reached 74.7391 million yuan, with the latest margin balance at 617 million yuan. (Data source: Wind)

As of March 23, Innovative Medicine ETF's net value has risen 5.49% over the past two years. In terms of return capability, as of March 23, 2026, since its inception, Innovative Medicine ETF's highest monthly return was 22.79%, the longest consecutive rising period was 4 months, the longest consecutive rising gain was 53.27%, and the average return rate during rising months was 6.61%. As of March 23, 2026, Innovative Medicine ETF's annualized excess return over the benchmark over the past two years was 0.57%.

In terms of drawdown, as of March 23, 2026, Innovative Medicine ETF's relative benchmark drawdown year-to-date was 0.08%.

In terms of fees, Innovative Medicine ETF has a management fee of 0.50% and a custody fee of 0.05%.

In terms of tracking accuracy, as of March 23, 2026, Innovative Medicine ETF's tracking error over the past five years was 0.037%, demonstrating relatively high tracking precision among comparable funds.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by Innovative Medicine ETF has a latest price-to-earnings ratio (PE-TTM) of only 45.1 times, at the 5.7th percentile over the past year, meaning the valuation is lower than 94.3% of the time over the past year, placing it at a historical low.

Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index. The CSI Innovative Medicine Industry Index selects up to 50 most representative listed company securities from among listed companies whose main business involves innovative medicine research and development as index samples to reflect the overall performance of innovative medicine industry listed company securities.

Industry institutions believe that the global biomedical industry is currently welcoming multiple catalysts. At the industry level, according to McKinsey consulting forecasts, dozens of blockbuster innovative medicines will intensively see key clinical data readouts and regulatory approvals in the next 2-3 years, with continuous technological breakthroughs in weight loss and metabolism, oncology, autoimmune and other fields. At the capital level, overseas interest rate cut cycles have begun, and historically, Hong Kong and U.S. biomedical assets have performed brightly during rate cut cycles, with high-elasticity innovative medicine assets expected to benefit.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.